VERA — Vera Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$34.13
-$0.10 (-0.29%)
Vera Therapeutics Inc (VERA) is a biotechnology company listed on NASDAQ. It is led by Marshall W. Fordyce M.D., based in 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005, with about 339 employees. Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Net income was -$80.3M. VERA currently screens at market cap $2.51B.
Use this VERA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the VERA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the VERA SEC filings page. Lician reads the product cache first so this HTML stays unique to Vera Therapeutics Inc even when a live quote feed is slow.
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
VERA Key Statistics
Market Cap
$2.51B
Volume
2.38M
Previous Close
$35.28
Day Range
$34.64 – $36.96
P/B Ratio
5.03
EPS
-$2.75
Revenue
$0.00
Net Income
-$152.15M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
339
VERA Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$152.15M | -$95.99M | -$89.06M | -$32.61M |
| EPS (Diluted) | -$2.75 | -$2.25 | -$3.35 | -$2.43 |
Total Assets
$655.68M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$92.65M
Operating Cash Flow
-$134.68M
Free Cash Flow
$0.00
Vera Therapeutics Inc Company Information
- Founder, President, CEO & Director
- Marshall W. Fordyce M.D.
- Headquarters
- 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
- Website
- veratx.com
- Phone
- 650 770 0077
- IPO / Founded
- 2021-05-14
- Sector
- Healthcare
- Industry
- Biotechnology